[Preclinical and clinical properties of elbasvir (ERELSA® Tablets 50 mg) and Grazoprevir (GRAZYNA® Tablets 50 mg), novel therapeutic agents for hepatitis C]

Nihon Yakurigaku Zasshi. 2017;150(1):41-53. doi: 10.1254/fpj.150.41.
[Article in Japanese]
No abstract available

MeSH terms

  • Amides
  • Antiviral Agents / adverse effects
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Benzofurans / adverse effects
  • Benzofurans / chemistry
  • Benzofurans / pharmacology
  • Benzofurans / therapeutic use*
  • Carbamates
  • Clinical Trials as Topic
  • Cyclopropanes
  • Drug Evaluation, Preclinical
  • Genotype
  • Hepacivirus / drug effects
  • Hepacivirus / physiology
  • Hepatitis C / drug therapy*
  • Humans
  • Imidazoles / adverse effects
  • Imidazoles / chemistry
  • Imidazoles / pharmacology
  • Imidazoles / therapeutic use*
  • Quinoxalines / adverse effects
  • Quinoxalines / chemistry
  • Quinoxalines / pharmacology
  • Quinoxalines / therapeutic use*
  • Sulfonamides
  • Virus Activation

Substances

  • Amides
  • Antiviral Agents
  • Benzofurans
  • Carbamates
  • Cyclopropanes
  • Imidazoles
  • Quinoxalines
  • Sulfonamides
  • grazoprevir
  • elbasvir